{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:26:17Z","timestamp":1790400377741,"version":"4.1.0"},"reference-count":28,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The safety of bevacizumab in combination with chemotherapy in patients with inflammatory bowel disease (IBD) and digestive and nondigestive cancers is poorly documented. Methods: We retrospectively evaluated patient records of all adult cancer patients with IBD at our institution from April 2007 to May 2016 with an update in November 2019. Results: Twenty-seven patients with a history of IBD (Crohn\u2019s disease, n = 22; ulcerative colitis, n = 5) who were treated with bevacizumab and chemotherapy for metastatic solid tumors were identified. At the time of advanced cancer diagnosis, 18 patients had quiescent IBD, whereas 9 patients had moderately active IBD. Among those with moderately active IBD, five had received corticosteroids less than six months prior to cancer diagnosis and one had received infliximab. The treated cancers were colorectal cancer (n = 13), small bowel cancer (n = 4), non-small cell lung cancer (n = 3), breast cancer (n = 3), and other cancers (n = 4). Patients received bevacizumab in combination with chemotherapy and\/or as maintenance for a median of 6.7 months. Grade 2 or higher bevacizumab-related complications were proteinuria in two patients and hypertension, diarrhea, rectal bleeding, and intestinal perforation in one patient each. No clinical IBD flares were observed during bevacizumab treatment. Conclusion: Bevacizumab combined with chemotherapy is safe in cancer patients with moderately active or quiescent IBD.<\/jats:p>","DOI":"10.3390\/cancers14122914","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T22:00:38Z","timestamp":1655157638000},"page":"2914","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6778-7704","authenticated-orcid":false,"given":"Ruth Gabriela","family":"Herrera-G\u00f3mez","sequence":"first","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, France"},{"name":"Oncology Department, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miruna","family":"Grecea","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, France"},{"name":"Oncology Institute \u2018Prof. Dr. I. Chiricuta\u2019, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gallois","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Digestive Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou, Assistance Publique\u2013H\u00f4pitaux de Paris, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pautier","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-7199","authenticated-orcid":false,"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-0130","authenticated-orcid":false,"given":"David","family":"Malka","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy Cancer Institute, 94805 Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.2019.37.4_suppl.664","article-title":"Safety of bevacizumab in cancer patients with inflammatory bowel disease","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory Bowel Disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"970890","DOI":"10.1155\/2015\/970890","article-title":"Angiogenesis in Inflammatory Bowel Disease","volume":"2015","author":"Alkim","year":"2015","journal-title":"Int. J. Inflamm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10456-014-9421-x","article-title":"Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis","volume":"17","author":"Ardelean","year":"2014","journal-title":"Angiogenesis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref_6","first-page":"127","article-title":"Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer","volume":"29","author":"Vermeire","year":"2016","journal-title":"Ann. Gastroenterol."},{"key":"ref_7","first-page":"348","article-title":"Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions","volume":"14","author":"Panes","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of Inflammatory Bowel Disease: A Comprehensive Review","volume":"8","author":"Cai","year":"2021","journal-title":"Front. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers Complicating Inflammatory Bowel Disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_10","first-page":"942","article-title":"Feasibility of Chemotherapy in Patients with Inflammatory Bowel Disease-Related Gastrointestinal Cancer","volume":"61","author":"Naito","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cgh.2012.06.016","article-title":"Effects of Cancer Treatment on Inflammatory Bowel Disease Remission and Reactivation","volume":"10","author":"Axelrad","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/ibd.21545","article-title":"Feasibility of anti-VEGF agent bevacizumab in patients with Crohn\u02bcs disease","volume":"17","author":"Coriat","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/annonc\/mdn566","article-title":"Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib","volume":"19","author":"Loriot","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease","volume":"38","author":"Faleck","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study","volume":"32","author":"Burger","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","article-title":"Bevacizumab in Patients with Nonsquamous Non\u2013Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study","volume":"21","author":"Besse","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00104-007-1339-z","article-title":"Ischemic anastomotic bowel perforation during treatment with bevacizumab 10 months after surgery","volume":"79","author":"Abbrederis","year":"2007","journal-title":"Der Chir."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.1988.6.2.291","article-title":"Emergency laparotomy for spontaneous intestinal and colonic perforations in cancer patients receiving corticosteroids and chemotherapy","volume":"6","author":"Torosian","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.crohns.2013.12.022","article-title":"Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease","volume":"8","author":"Rajca","year":"2014","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-0040-1713748","article-title":"Colorectal Cancer in Inflammatory Bowel Disease","volume":"33","author":"Nebbia","year":"2020","journal-title":"Clin. Colon Rectal Surg."},{"key":"ref_24","first-page":"3333","article-title":"Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease","volume":"60","author":"Hussain","year":"2000","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/cncr.10334","article-title":"The APC\/\u03b2-catenin pathway in ulcerative colitis-related colorectal carcinomas: A mutational analysis","volume":"94","author":"Aust","year":"2002","journal-title":"Cancer"},{"key":"ref_26","first-page":"4864","article-title":"Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1","volume":"60","author":"Fleisher","year":"2000","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00384-016-2574-x","article-title":"Colorectal cancer in Crohn\u2019s colitis is comparable to sporadic colorectal cancer","volume":"31","author":"Lennerz","year":"2016","journal-title":"Int. J. Color. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"22175","DOI":"10.18632\/oncotarget.14549","article-title":"KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: A meta-analysis","volume":"8","author":"Du","year":"2017","journal-title":"Oncotarget"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/12\/2914\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:30:33Z","timestamp":1760139033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/12\/2914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14122914"],"URL":"https:\/\/doi.org\/10.3390\/cancers14122914","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}